Incidence and endovascular treatment of severe spontaneous non-cerebral bleeding: a single-institution experience
- 25 Downloads
To investigate the incidence and endovascular treatment of severe spontaneous non-cerebral hemorrhage (SSNCH) in a high-volume, tertiary university hospital.
All patients diagnosed with SSNCH between January 2016 and June 2017 were retrospectively analyzed. Endovascular treatment (group EVT) was offered only in patients demonstrating active bleeding at CT angiography (CTA). In cases without active bleeding at CTA, conservative management was decided (group CM). Outcome measures included the incidence of SSNCH, 6-month rebleeding, and survival rates in the two groups as well as EVT technical success and related complications.
Within the 18-month period, 44 SSNCH cases were identified, resulting in an annual incidence of 29.3 cases. In 37/44 cases (84.1%), bleeding was attributed to the antithrombotic therapy. In total, 19/44 patients underwent EVT (43.2%), and 25/44 patients (56.8%) were managed conservatively. Two patients who were initially treated conservatively finally underwent EVT due to rebleeding (7.4%). The technical success of EVT was 100%, while rebleeding occurred in 1 case (5.2%) following lumbar artery embolization and was successfully re-embolized. According to the Kaplan-Meier analysis, the 1-, 3-, and 6-month survival rates were 68.4%, 63.2%, and 42.1% for group EVT and 87.5%, 75.0%, and 58.3% for group CM, respectively. There were no EVT-related complications.
The annual incidence of SSNCH in our institution is substantial. EVT resulted in uncomplicated, high bleeding control rates. The mortality rate was similarly high following either EVT or conservative treatment and was mainly attributed to severe comorbidities.
• This study demonstrates that the incidence of severe spontaneous non-cerebral hemorrhage (SSNCH) in our institution is substantial.
• Endovascular treatment was offered only in patients with clinical signs of ongoing hemorrhage and active bleeding at CT angiography and resulted in effective and uncomplicated, minimal invasive hemostasis, in a population with severe comorbidities.
• This is the first study to evaluate the outcomes of both endovascular hemostasis and conservative management. Rebleeding following either conservative or endovascular treatment was minimal.
KeywordsHemorrhage Therapeutic embolization Anticoagulant drugs
Common femoral artery
Digital subtraction angiography
Low molecular weight heparin
Multi-detector computerized tomography angiography.
New oral anticoagulants
Non-steroid anti-inflammatory drugs
Profunda femoralis artery
Severe, spontaneous, non-cerebral hemorrhage
von Willebrand factor
The authors state that this work has not received any funding.
Compliance with ethical standards
The scientific guarantor of this publication is Professor Elias Brountzos.
Conflict of interest
The authors declare that they have no conflict of interest.
Statistics and biometry
No complex statistical methods were necessary for this paper.
Written informed consent was obtained from all patients in this study.
Institutional Review Board approval was obtained.
• Case-control study
• Performed at one institution
- 5.Crowther MA, Warkentin TE (2008) Bleeding risk and the management of bleeding complications in patients undergoing anticoagulant therapy: focus on new anticoagulant agents. Blood 111:4871–4879Google Scholar
- 6.Gerhard-Herman MD, Gornik HL, Barrett C et al (2017) 2016 AHA/ACC guideline on the management of patients with lower extremity peripheral artery disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. Circulation 135(12):e726–e779PubMedGoogle Scholar
- 7.Shojania KG, Duncan BW, McDonald KM, Wachter RM, Markowitz AJ (2001) Making health care safer: a critical analysis of patient safety practices. Evid Rep Technol Assess (Summ) 43:1–668Google Scholar
- 10.Andreou I, Briasoulis A, Pappas C, Ikonomidis I, Alexopoulos D (2018) Ticagrelor versus clopidogrel as part of dual or triple antithrombotic therapy: a systematic review and meta-analysis. Cardiovasc Drugs Ther. https://doi.org/10.1007/s10557-018-6795-9
- 18.Pernod G, Godiér A, Gozalo C, Tremey B, Sié P, French National Authority for Health (2010) French clinical practice guidelines on the management of patients on vitamin K antagonists in at-risk situations (overdose, risk of bleeding, and active bleeding). Thromb Res 126(3):e167–e174CrossRefPubMedGoogle Scholar
- 19.Keeling D, Baglin T, Tait C et al (2012) British Committee for Standards in Haematology. Guidelines on oral anticoagulation with warfarin–4th edition. Br J Haematol 160:35–46Google Scholar